A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Ruxolitinib (Primary) ; Regorafenib
- Indications Colorectal cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Incyte Corporation
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
- 18 Jan 2017 This trial has been completed in Spain (end date: 17 Dec 2016).
- 16 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.